Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2/3 1Phase 1 1

Status

Unknown 11Recruiting 7Terminated 6Not yet recruiting 6Completed 6

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 2Other hematologic neoplasm 1Endocrine 1

Conditions

Stomach Neoplasms 1Nasopharyngeal Carcinoma 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Differentiated Thyroid Cancer 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Interventional × donafenib × Clear all
NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Peking University

Phase 2/3 Terminated
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02489201 2023-06-15

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
19 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02489214 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02698111 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04402723 2022-12-01

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1 Terminated
8 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated
204 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡